Glycine Antagonist in Neuroprotection for Patients with Acute Stroke "GAIN Americas"


Phase 3 Results

Summary of Purpose

To evaluate the efficacy and safety of gavestinel in patients with a clinical diagnosis of acute stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 August 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics



  • Glaxo Wellcome, Research Triangle, NC

Trial Design

Stratified, randomized, international, double-blind, placebo controlled trials of 1367 patients at 132 centers. Patients were stratified by age (75 vs >75 years) and initial stroke severity (National Institutes of Health [NIH] Stroke Scale scores of 2-5, 6-13, or 14).


  • Ralph L. Sacco, MD, MS, The Neurological Institute, Columbia University, 710 W 168th St, Room 547, New York, NY 10032.